Zymeworks
ZYME on Nasdaq. Zymeworks sells biotherapeutics for cancer and autoimmune diseases to patients and partners. Market value $1.8bn.
Price checks use the past 12 months to September 2026. Quality checks use five annual reports, the latest for the year to December 2025.
We can't read total debt from the filing, so debt is left out.
Should I look at this?
Not a fit for our list right now
Why it could be worth it
Nothing stands out yet.
See Health care stocks that passed both tests
This is not advice. Check the numbers below.
For every $100 of what the whole company costs, it produced $-6.25 of spare cash in the past 12 months. A savings account pays about $4.
You pay 46.3 years of operating profit for the business. The average large US company costs around 18.
The filings do not give us enough to work this out.
Quality score: 25 of 100. Price score: 13 of 100. Our list needs 70 on quality and 60 on price.
$26.14 a share, 21% above its 1-year low
Over the past year the price has ranged from $21.52 to $31.97.
Pays no dividend
Prices from Friday’s close (20 November).
Five years of cash, in billions
Spare cash swings from quarter to quarter here: a shortfall of $113 million in the past 12 months, a shortfall of $35 million in the year to December 2025.
| Revenue | ||||
| Revenue | $412m | $76m | $76m | $106m |
| Operating margin | ||||
| Operating margin | 31.6% | -181.6% | -179.7% | -87.3% |
| Debt to equity | ||||
| Debt to equity | n/a | n/a | n/a | n/a |
| Shares outstanding | ||||
| Shares outstanding | 0.07bn | 0.07bn | 0.07bn | 0.07bn |
Health checks
- Free cash flow positive1 of 4 years
- Accounting checksSkipped: company is not yet profitable
- DebtUnknown
- Revenue growth, five yearsShrinking, 36.4% a year
- Buying back its own sharesRoughly flat
The quarter to September 2026
How the business did, compared with the same quarter a year earlier.
- Sales: $256 million last quarter, up 829% on a year ago.
- Profit: $174 million, after a loss of $20 million a year ago.
- It keeps 17 cents of each $1 of sales as operating profit, after losing 53 cents a year earlier.
- Over the past 12 months it spent $113 million more cash than it brought in, compared with $66 million a year earlier.
- 1% more shares than a year ago. Each share owns a bit less of the company.
- Sales grew on a year ago in 1 of the last 4 quarters.
| Quarter to | Amount |
|---|---|
| December 2024 | $31m |
| March 2025 | $27m |
| June 2025 | $49m |
| September 2025 | $28m |
| December 2025 | $3m |
| March 2026 | $2m |
| June 2026 | $5m |
| September 2026 | $256m |
| Quarter to | Amount |
|---|---|
| December 2024 | -$24m |
| March 2025 | -$23m |
| June 2025 | $2m |
| September 2025 | -$20m |
| December 2025 | -$41m |
| March 2026 | -$44m |
| June 2026 | -$45m |
| September 2026 | $174m |
From the company's quarterly reports to the SEC.
Dates
- Next results (estimated)
- n/a
- Last annual report (10-K)
- 2 March 2026
- Next quarterly (estimated, 10-Q)
- 8 February 2027
Who owns it
1 long-term investor we follow owns it, down from 2 last quarter. 203 funds in all.
- Platinum Investment ManagementPlatinum team
- Value
- $3m
- Share of fund
- 0.7%
| Fund | Value | Share of that fund | Change |
|---|---|---|---|
| Platinum Investment ManagementPlatinum team | $3m | 0.7% |
Sold out this quarter
- Royce & AssociatesChuck RoyceSold out
Largest holders overall
- EcoR1 Capital$600m
- Rubric Capital Management LP$183m
- BlackRock$111mCut
- Perceptive Advisors$109mAdded
- BVF$95mCut
- Assenagon Asset Management$65mAdded
- Morgan Stanley$58mCut
- BNP PARIBAS ASSET MANAGEMENT Holding$47mCut
- Vanguard Capital Management$41mCut
- Nextech Invest$29m
From 13F filings for the quarter ended 30 June 2026.
Big holders and activists
5 investors own more than 5%.
- EcoR1 Capital, LLCPassive investorat least 30.7%0.0 pts(filed with 2 related holders)Since 16 November 2025
What they said
Scott Platshon, one of EcoR1's employees, resigned from the Issuer's board of directors as of November 16, 2025. Concurrently with his resignation, Mr. Platshon was appointed as the Issuer's Acting Chief Investment Officer. Oleg Nodelman, the manager of EcoR1, is a member of the…
Read the filing - Rubric Capital Management LPPassive investorat least 9.5%+1.8 pts(filed with 1 related holder)Since 31 March 2026
- Perceptive Advisors LLCPassive investorat least 5.4%(filed with 2 related holders)Since 8 April 2026
- BVF PARTNERS L P/ILPassive investorat least 5.2%(filed with 9 related holders)Since 30 September 2025
- Redmile Group, LLCPassive investorat least 4.9%−0.7 pts(filed with 1 related holder)Since 30 September 2025
- BlackRock, Inc.Passive investorSold down below 5%Since 30 June 2025
- Redmile Biopharma Investments III, L.P.Passive investorSold down below 5%Since 30 June 2025
- Morgan Stanley Capital Services LLCPassive investorSold down below 5%Since 31 March 2025
- Morgan StanleyPassive investorSold down below 5%Since 31 December 2025
| Holder | Stake | Since | |
|---|---|---|---|
EcoR1 Capital, LLC Passive investor | at least 30.7%0.0 pts (filed with 2 related holders) | 16 November 2025 | What they saidScott Platshon, one of EcoR1's employees, resigned from the Issuer's board of directors as of November 16, 2025. Concurrently with his resignation, Mr. Platshon was appointed as the Issuer's Acting Chief Investment Officer. Oleg Nodelman, the manager of EcoR1, is a member of the… Read the filing |
Rubric Capital Management LP Passive investor | at least 9.5%+1.8 pts (filed with 1 related holder) | 31 March 2026 | |
Perceptive Advisors LLC Passive investor | at least 5.4% (filed with 2 related holders) | 8 April 2026 | |
BVF PARTNERS L P/IL Passive investor | at least 5.2% (filed with 9 related holders) | 30 September 2025 | |
Redmile Group, LLC Passive investor | at least 4.9%−0.7 pts (filed with 1 related holder) | 30 September 2025 | |
BlackRock, Inc. Passive investor | Sold down below 5% | 30 June 2025 | |
Redmile Biopharma Investments III, L.P. Passive investor | Sold down below 5% | 30 June 2025 | |
Morgan Stanley Capital Services LLC Passive investor | Sold down below 5% | 31 March 2025 | |
Morgan Stanley Passive investor | Sold down below 5% | 31 December 2025 |
From Schedule 13D and 13G filings: anyone owning more than 5% must file one.
What insiders did
No insider bought shares on the open market in the last 12 months. 6 sold $6m.
- Platshon ScottEVP, Chief Business OfficerSold
- Date
- 18 November 2026
- Shares
- 15,292
- Price
- $24.95
- Value
- $381,535
- Moore Paul AndrewChief Scientific OfficerSold
- Date
- 13 November 2026
- Shares
- 39,741
- Price
- $26.07
- Value
- $1m
- Schayowitz AdamEVP, Head of R&DSold
- Date
- 9 October 2026
- Shares
- 13,832
- Price
- $25.85
- Value
- $357,557
- Hollywood MarkEVP & Chief Operating OfficerSold
- Date
- 12 January 2026
- Shares
- 6,120
- Price
- $22.67
- Value
- $138,740
- Smith Jeffrey T LEVP & Chief Medical OfficerSold
- Date
- 12 January 2026
- Shares
- 9,310
- Price
- $22.67
- Value
- $211,058
- Moore Paul AndrewChief Scientific OfficerSold
- Date
- 12 January 2026
- Shares
- 9,560
- Price
- $22.67
- Value
- $216,725
- Galbraith KennethChair & CEO, DirectorSold
- Date
- 12 January 2026
- Shares
- 30,424
- Price
- $22.67
- Value
- $689,712
- Smith Jeffrey T LEVP & Chief Medical OfficerSold
- Date
- 5 January 2026
- Shares
- 10,538
- Price
- $25.10
- Value
- $264,504
- Galbraith KennethChair & CEO, DirectorSold
- Date
- 5 January 2026
- Shares
- 54,343
- Price
- $25.10
- Value
- $1m
- Moore Paul AndrewChief Scientific OfficerSold
- Date
- 5 January 2026
- Shares
- 20,110
- Price
- $25.10
- Value
- $504,761
| Date | Who | Did | Shares | Price | Value |
|---|---|---|---|---|---|
| 18 November 2026 | Platshon Scott EVP, Chief Business Officer | Sold | 15,292 | $24.95 | $381,535 |
| 13 November 2026 | Moore Paul Andrew Chief Scientific Officer | Sold | 39,741 | $26.07 | $1m |
| 9 October 2026 | Schayowitz Adam EVP, Head of R&D | Sold | 13,832 | $25.85 | $357,557 |
| 12 January 2026 | Hollywood Mark EVP & Chief Operating Officer | Sold | 6,120 | $22.67 | $138,740 |
| 12 January 2026 | Smith Jeffrey T L EVP & Chief Medical Officer | Sold | 9,310 | $22.67 | $211,058 |
| 12 January 2026 | Moore Paul Andrew Chief Scientific Officer | Sold | 9,560 | $22.67 | $216,725 |
| 12 January 2026 | Galbraith Kenneth Chair & CEO, Director | Sold | 30,424 | $22.67 | $689,712 |
| 5 January 2026 | Smith Jeffrey T L EVP & Chief Medical Officer | Sold | 10,538 | $25.10 | $264,504 |
| 5 January 2026 | Galbraith Kenneth Chair & CEO, Director | Sold | 54,343 | $25.10 | $1m |
| 5 January 2026 | Moore Paul Andrew Chief Scientific Officer | Sold | 20,110 | $25.10 | $504,761 |
From Form 4 filings: insiders must report trades in their own company's shares within two days.
Warning signs in its filings
Problems the company itself reported to the SEC, in its own words.
We couldn’t fully check Zymeworks’ latest annual report.
We look for five warning signs: doubt it can keep going, weak checks on its own accounts, a notice that its past accounts can't be relied on, a change of auditor, and one customer bringing in a big share of sales. We don't check lawsuits, investigations or debt yet.
We couldn't fully read the 10-K filed 2 Mar 2026, so we can't say there are no warning signs.
A 10-K is the yearly report every US company files with the SEC. An 8-K is a short notice of a big event.
What could go wrong
- Sales have shrunk: 36.4% a year.
- It isn't cheap on profits: 46.3× operating profit.
Whether the price already reflects the risks is what the deep dive is for.
The deep dive
Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.
- What the business is worth, as a range, and the margin of safety at today’s price
- Prices to start buying, buy, and buy hard
- The three things that would make this a mistake
- Every number footnoted to the filing it came from
Your first deep dive is free.
Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.